ライフサイエンスコーパス: withdrawal symptom

1 ge, 0-51; higher scores indicate more severe withdrawal symptoms).

2 id-mediated effects, including analgesia and withdrawal symptoms.

3 caine-dependent patients with severe cocaine withdrawal symptoms.

4 n heart rate (HR), and characteristic opiate withdrawal symptoms.

5 ed in an even more impressive suppression of withdrawal symptoms.

6 vely reduced the expression of certain other withdrawal symptoms.

7 nergic neurons in the expression of morphine withdrawal symptoms.

8 3alpha, 5alpha-THP) that produces anxiogenic withdrawal symptoms.

9 actice of drug holidays and reports of acute withdrawal symptoms.

10 epines and ethanol can also produce PMS-like withdrawal symptoms.

11 n to decrease the expression of precipitated withdrawal symptoms.

12 sed to underlie the manifestation of ethanol withdrawal symptoms.

13 se synapses and robustly suppresses morphine withdrawal symptoms.

14 716 significantly attenuated somatic alcohol withdrawal symptoms.

15 ve therapy for up to 5 days or resolution of withdrawal symptoms.

16 of tramadol ER as a method to manage opioid withdrawal symptoms.

17 er was correlated with decreased craving and withdrawal symptoms.

18 on of pleasure from cigarettes and relief of withdrawal symptoms.

19 may contribute to amelioration of subjective withdrawal symptoms.

20 ues, and both decreasing dACC GABA and early withdrawal symptoms.

21 because of its association with less severe withdrawal symptoms.

22 duced IPN neuronal activation and alleviated withdrawal symptoms.

23 the thalamus and brainstem without reducing withdrawal symptoms.

24 low-dose varenicline, significantly reduced withdrawal symptoms.

25 ence, medication diversion, and emergence of withdrawal symptoms.

26 the intensity of running and the severity of withdrawal symptoms.

27 ptor subunits expressed therein, in nicotine withdrawal symptoms.

28 ne was released in the vBNST during specific withdrawal symptoms.

29 ntial therapeutic agents in treating alcohol withdrawal symptoms.

30 eceptor-facilitating agents suppress alcohol withdrawal symptoms.

31 line receptors in the appearance of nicotine withdrawal symptoms.

32 abuse and the manifestations of opiate/drug withdrawal symptoms.

33 we show that induction of physical nicotine withdrawal symptoms activates GABAergic neurons within t

34 As in humans, rodents undergo physical withdrawal symptoms after cessation from chronic nicotin

35 t presented twice with toxic effects and had withdrawal symptoms after her second presentation.

36 Stronger nicotine withdrawal symptoms among the depressed smokers contribu

37 ion is strongly influenced by a reduction in withdrawal symptoms, an expectation of stress reduction,

38 lone administration would decrease marijuana withdrawal symptoms and a laboratory measure of marijuan

39 e produced a robust attenuation of marijuana withdrawal symptoms and a laboratory measure of relapse

40 ents of cigarette smoke significantly impact withdrawal symptoms and associated brain areas, independ

41 ficacy (tolerance), as well as physiological withdrawal symptoms and behavioral manifestations such a

42 and function, playing a crucial role in EtOH withdrawal symptoms and dependence.

43 ve treatments merit exploration for reducing withdrawal symptoms and drinking in alcohol-dependent in

44 rticipants in both groups reported relief of withdrawal symptoms and drug-related human immunodeficie

45 erneurons, may be beneficial for alleviating withdrawal symptoms and facilitating smoking cessation.

46 of varenicline for managing global nicotine withdrawal symptoms and for smoking cessation, its effec

47 eking cohort, nabiximols attenuated cannabis withdrawal symptoms and improved patient retention in tr

48 ectiveness of amantadine in reducing cocaine withdrawal symptoms and improving treatment outcome amon

49 jects with the highest scores on measures of withdrawal symptoms and of addiction severity that have

50 en or are being developed to relieve smoking withdrawal symptoms and promote abstinence from smoking.

51 aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding propertie

52 ncing the methadone dose required to prevent withdrawal symptoms and relapse in this population.

53 ent treatments rely on suppressing immediate withdrawal symptoms and replacing illicit drug use with

54 ation and nicotine on suppression of tobacco withdrawal symptoms and smoking behavior.

55 ate drug (that is, without relapse or severe withdrawal symptoms) and clinical outcomes (neuropsychia

56 ithdrawal (group 1), 51.3% of whom evidenced withdrawal symptoms, and 446 subjects (13.1%) without a

57 d significant decreases in illicit drug use, withdrawal symptoms, and depression.

58 Alcohol craving, addiction, and withdrawal symptoms are affected by serotonin concentrat

59 Although withdrawal symptoms are commonly reported by persons see

60 that drug pleasure and subsequent unpleasant withdrawal symptoms are the chief causes of addiction; (

61 the mechanism and neuroanatomical bases for withdrawal symptoms are unclear.

62 rview (p=0.004), and significantly decreased withdrawal symptoms as measured by the Marijuana Withdra

63 ment, pregabalin does not appear to have the withdrawal symptoms associated with the benzodiazepines.

64 ime to relapse (P = 0.0002) and an impact on withdrawal symptoms at target quit date (TQD) (P = 0.000

65 Among subjects with severe cocaine withdrawal symptoms at the start of treatment, those who

66 he six subjects experienced mild to moderate withdrawal symptoms between the third and fifth days of

67 t cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dep

68 Nicotine withdrawal symptoms can also be observed in rodents.

69 ealthy behaviours, detoxification to address withdrawal symptoms, cognitive-behavioural therapies to

70 Withdrawal symptoms complicated conversion from predniso

71 Nicotine withdrawal symptoms contribute to relapse in smokers, th

72 Both norepinephrine and withdrawal symptoms could be elicited in the absence of

73 elapse to smoking was predicted by increased withdrawal symptoms, decreased left DLPFC and increased

74 eceptor occupancy by varenicline and tobacco withdrawal symptoms ((*)denoting other putative nAChR su

75 The expression of somatic withdrawal symptoms depends mainly on the alpha5, alpha2

76 companied by a threefold reduction in opiate withdrawal symptoms despite normal antinociceptive toler

77 Patients with stronger withdrawal symptoms displayed the largest volume increas

78 mparable to buprenorphine in reducing opioid withdrawal symptoms during a residential tapering progra

79 s the dopaminergic reward system by reducing withdrawal symptoms during abstinence and by decreasing

80 lcohol self-administration and physiological withdrawal symptoms during acute withdrawal and protract

81 withdrawal phenomena, reduction in nicotine withdrawal symptoms during smoking cessation, analgesia,

82 tive food-restricted rats displayed the most withdrawal symptoms, followed by active rats given 24-hr

83 drugs can lead to dependence as indicated by withdrawal symptoms following cessation and tolerance to

84 assess the addictive potential of exercise, withdrawal symptoms following injections of 1.0 mg/kg na

85 (72 hr) of withdrawal, even though physical withdrawal symptoms had resolved at this time point.

86 rated (P <.001) and patient-rated (P = .004) withdrawal symptoms, had lower patient ratings of cravin

87 Drug administration to avoid unpleasant drug withdrawal symptoms has been hypothesized to be a crucia

88 Increased anxiety is a prominent withdrawal symptom in abstinent smokers, yet the neuroan

89 lation of channelrhodopsin elicited physical withdrawal symptoms in both nicotine-naive and chronic-n

90 ecommend a pharmacologic regimen titrated to withdrawal symptoms in ICU patients with alcohol withdra

91 cohol self-administration from physiological withdrawal symptoms in relation to KOR signaling in the

92 Nevertheless, nicotine-withdrawal symptoms, including depressed mood, anxiety,

93 A history of major depression and persistent withdrawal symptoms independently predicted posttreatmen

94 o chronic ethanol consumption that underlies withdrawal symptoms, is thought to directly contribute t

95 Retention, withdrawal symptom management, concomitant medication ut

96 t is thought that the modulation of nicotine withdrawal symptoms may contribute to their effectivenes

97 ng effects of a drug and the desire to avoid withdrawal symptoms motivate continued drug use, and the

98 The time course of withdrawal symptom onset and the rationale for drug holi

99 uding voluntary ethanol consumption, ethanol withdrawal symptoms, operant ethanol self-administration

100 Although no physical withdrawal symptoms or alterations in the plasma cortico

101 Some withdrawal symptoms or relapses may have been missed.

102 he role of this pathway in mediating ethanol withdrawal symptoms (physical dependence).

103 42 = -0.32, P < .05) and more severe alcohol-withdrawal symptoms (r38 = -0.35, P < .05).

104 cits in learning, are one of the most common withdrawal symptoms reported by smokers.

105 n addict to escape from and avoid the severe withdrawal symptoms resulting from opiate dependence.

106 ovement), and Michelson SSRI (Selective SRI) Withdrawal Symptoms Scale scores (range, 0-51; higher sc

107 es in symptomatic days or the Michelson SSRI Withdrawal Symptoms Scale.

108 Sertraline treatment produced a lower total withdrawal symptom score and less irritability, anxiety,

109 d repeated self-report measures (ie, tobacco withdrawal symptoms, smoking urge, and negative affect (

110 severity, function, quality of life, opioid withdrawal symptoms, substance use, and adverse events.

111 Smoking cessation results in withdrawal symptoms such as craving and negative mood th

112 ine users, which might contribute to cocaine withdrawal symptoms such as depression and suicidality.

113 sm requires the proper management of ethanol withdrawal symptoms, such as anxiety, to prevent further

114 It also produced less severe opioid withdrawal symptoms than naloxone in morphine-dependent

115 gonists might be useful for the treatment of withdrawal symptoms that contribute to the maintenance o

116 rug-associated cues can elicit the emotional withdrawal symptoms that promote cocaine use.

117 is generally directed at the suppression of withdrawal symptoms through maintenance of the 'addicted

118 evelopment of tolerance and the emergence of withdrawal symptoms upon cessation of chronic nicotine a

119 Psychiatric evaluation to assess withdrawal symptoms was also done at each scanning sessi

120 .05; P < .001 for all), although duration of withdrawal symptoms was greater at higher doses (eta2 =

121 Subjective measures of smoking withdrawal symptoms were also collected.

122 Cannabis withdrawal symptoms were assessed using the Marijuana Wi

123 oral-cecal transit time, and central opioid withdrawal symptoms were compared between the 2 groups.

124 162) on voluntary ethanol intake and ethanol withdrawal symptoms were evaluated in rats voluntarily c

125 cy for smoking abstinence and its effects on withdrawal symptoms were evaluated.

126 reased mRNA expression and the appearance of withdrawal symptoms were inhibited.

127 Only minimal withdrawal symptoms were observed in inactive rats.

128 No withdrawal symptoms were reported after treatment discon

129 tive components of naloxone-induced morphine withdrawal symptoms were significantly attenuated in M5-

130 y (urine toxicology, retention, craving, and withdrawal symptoms) were examined at the study midpoint

131 lleviating incisional pain and narcotic drug withdrawal symptoms, which are now in clinical trials.

132 investigate the effect of MT-7716 on alcohol withdrawal symptoms, Wistar rats were withdrawn from a 7

133 rs, there is evidence for the association of withdrawal symptoms with MDMA abstinence.

134 ful attempts to cut down use, tolerance, and withdrawal symptoms), with ORs ranging between 1.6 (95%

135 binol (THC; dronabinol), decreases marijuana withdrawal symptoms, yet does not decrease marijuana use